Tumour-suppressor proteins articles from across Nature Portfolio

Increased tRNA abundance and amino acid coupling generally promote increased oncogenesis. By contrast, a new study shows that in breast cancer, the leucyl-tRNA synthetase LARS suppresses transformation and tumour development by increasing tRNA-Leu^CAG translation of certain tumour suppressor mRNAs.

A genome-wide CRISPR screen finds CIP2A as a new synthetic lethal target for BRCA1- and BRCA2-deficient cells. Unlike PARP inhibition that increases replication-induced DNA double-strand breaks and radial chromosomes, depleting CIP2A or disrupting its interaction with TOPBP1 increases micronuclei and chromosomal missegregation, revealing a mitotic target for BRCA-mutated tumors.

Two recent studies have found that both the adaptive immune system and inflammation can drive the selection of cells carrying mutations that facilitate tumour initiation.

FTO, an m⁶A RNA demethylase, is known mainly as an oncoprotein in various cancer types. FTO is now shown to act as a cancer suppressor in a subset of epithelial tumors through an interplay between epithelial-to-mesenchymal transition and Wnt signaling.

Two recent papers describe the development of bispecific antibodies that specifically target neoantigens derived from common oncogenic mutations.